Author

Jianing Xu

Memorial Sloan Kettering Cancer CenterPrimary ORCID profile (0000-0003-2547-4344 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Jianing XuiD1 paper · Shandong University

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

Alexander Edward Dela Cruz DriloniD· 1 shared Ann BialikiD· 1 shared Corina AmoriD· 1 shared Douglas Warner· 1 shared Ed ReznikiD· 1 shared Elisa de StanchinaiD· 1 shared Emily H. Y. ChengiD· 1 shared Ezra Y. RoseniD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander Edward Dela Cruz DrilonORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 28, 2026

Combined Loss of VHL and TSC1 Drives Clear Cell Renal Cell Carcinoma with Metabolic and Redox Reprogramming that Creates an NRF2 Dependency

Jianing Xu, Xiaoqing Cheng, Omran Abu Aboud…·James J.-D. Hsieh

This study creates a mouse model of VHL-/-TSC1-/- ccRCC, identifies metabolic and redox reprogramming, and highlights NRF2 as a therapeutic target.

DOI 10.64898/2026.09.24.754188

mousebulk RNA-seq

𝕏 PostBluesky

Systems BiologybioRxivPreprintMar 18, 2026

A stem cell aging clock links biological age deviation to clinical outcome in acute myeloid leukemia

Hongcheng Chen, Pengwei Dong, Jianing Xu, Guanlin Wang

The paper develops a stem cell aging clock using single-cell transcriptomics to predict clinical outcomes in AML by measuring transcriptional age deviation.

DOI 10.64898/2026.02.12.703707

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologyProceedings of the National Academy of SciencesPeer-reviewedJul 21, 2025

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer

Jacob A. Boyer, Ezra Y. Rosen, Malvika Sharma…·Neal X. Rosen

This paper identifies eIF4A as a key regulator of ER translation in breast cancer and shows that inhibiting eIF4A, either alone or with fulvestrant, suppresses ER expression and tumor growth in advanced ER+ breast cancer.

16 citationstop 1%

humanproteomics

𝕏 PostBluesky